-
International NASH Day 2022 – Enabling therapies for patients
Non-alcoholic steatohepatitis, or NASH, remains a disease with no approved therapeutics. And it’s been a tough area for drug development,…
-
NASH – Challenges for drug development
It’s International NASH Day – and it’s also a while since we have last discussed NASH on the blog. In…
-
International NASH Day 2019
On International NASH Day 2019 we discuss the mixed outcomes of NASH drug clinical trials and how we believe a…
-
Recent study highlights the challenges in developing treatments for NASH
We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated…
-
TherapeutAix NASH review article is now available online!
At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug…
-
Navigating the NASH Maze
The availability of 2 approved medicines for the treatment of idiopathic pulmonary fibrosis (IPF) has stimulated an explosion in fibrosis…
-
TherapeutAix to attend the Extracellular Matrix Pharmacology Symposium
TherapeutAix is attending the Extracellular Matrix Pharmacology Symposium hosted by network partner Nordic Bioscience on March 24th – 25th. The online symposium will centre on…
-
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
-
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
-
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak…
